Evidence map›Paper›PMID 38520655›Full record

ArticleJournal of endocrinological investigation2024

Rachel score: a nomogram model for predicting the prognosis of lung neuroendocrine tumors.

A La Salvia, B Marcozzi, C Manai, R Mazzilli, L Landi, M Pallocca, G Ciliberto, F Cappuzzo, A Faggiano

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Observational
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

A La Salvia *Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy. anna.lasalvia@iss.it.ORCID http://orcid.org/0000-0002-5020-8657
B Marcozzi *Biostatistics, Bioinformatics and Clinical Trial Center, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
C ManaiMedical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
R MazzilliDepartment of Clinical and Molecular Medicine, Sant'Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy.
L LandiMedical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
M PalloccaBiostatistics, Bioinformatics and Clinical Trial Center, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
G CilibertoScientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
F CappuzzoMedical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
A FaggianoDepartment of Clinical and Molecular Medicine, Sant'Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITAzienda Ospedaliera Sant'Andrea · ITNational Institute of Health · AM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung NET, classified in typical carcinoids (TC) and atypical carcinoids (AC), are highly heterogeneous in their biology and prognosis. The histological subtype and TNM stage are well-established prognostic factors for lung NET. In a previous work by our group, we demonstrated a significant impact of laterality on lung NET survival outcomes. MATERIALS AND

methodsWe developed a nomogram that integrates relevant prognostic factors to predict lung NET outcomes. By adding the scores for each of the variables included in the model, it was possible to obtain a prognostic score (Rachel score). Wilcoxon non-parametric statistical test was applied among parameters and Harrell's concordance index was used to measure the models' predictive power. To test the discriminatory power and the predictive accuracy of the model, we calculated Gonen and Heller concordance index. Time-dependent ROC curves and their area under the curve (AUC) were used to evaluate the models' predictive performance.

resultsBy applying Rachel score, we were able to identify three prognostic groups (specifically, high, medium and low risk). These three groups were associate to well-defined ranges of points according to the obtained nomogram (I: 0-90, II: 91-130; III: > 130 points), providing a useful tool for prognostic stratification. The overall survival (OS) and progression free survival (PFS) Kaplan-Meier curves confirmed significant differences (p < 0.0001) among the three groups identified by Rachel score.

conclusionsA prognostic nomogram was developed, incorporating variables with significant impact on lung NET survival. The nomogram showed a satisfactory and stable ability to predict OS and PFS in this population, confirming the heterogeneity beyond the histopathological diagnosis of TC vs AC.

Indexed as

Lung NeoplasmsNeuroendocrine TumorsNomogramsAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisROC CurveSurvival RateLung NETNeuroendocrine tumorsNomogramPrimary tumor locationPrognostic score

Identifiers

PMID38520655
OpenAlexW4393118838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.